ratio increased from 7.2 percent to 7.9 percent. The United States had both the largest absolute and second-largest percentage increase in its ratio. No other country spent more than 10 percent of GDP on health care in 1991. Exhibit 2 presents per capita health spending denominated in U.S. dollars on the basis of GDP purchasing power parities (PPPs) for [1985] [1986] [1987] [1988] [1989] [1990] [1991] Un it ed United C a n a d a F r a n c e G e r m a n y J a p a n K i n g d o m S t a t e s Nominal per capita health spending 7.5% 6 . 9 % 4 . 9 % 6 . 2 % 9 . 9 % 9.0% Real (medical price deflator) per capita health spending 2. provides a measure of the increase in actual spending per person in each country's own currency. Adjusting this figure for medical price inflation provides a measure of the increase in the volume and intensity of health services per person. Deflating nominal per capita health expenditures by the GDP deflator provides a measure of the nonhealth-sector consumption and investment opportunities that have been forgone because of the growth in health spending. Excess health care inflation measures the rate of growth of medical prices relative to overall prices as measured by the GDP deflator. The nominal elasticity of per capita health spending relative to per capita GDP relates annual increases in nominal per capita health spending to annual increases in nominal per capita GDP. 3 In the context of three of these five measures, U.S. spending growth far exceeded growth in the other five countries. The United States had the highest rates of growth in real (GDP deflator-adjusted) health spending and excess medical care inflation, as well as the highest nominal elasticity of health spending relative to GDP. In light of the fact that the United States had the highest 1985 base-year spending level and growth rates in its health-to-GDP ratio and per capita health spending in U.S. dollars (Exhibits 1 and 2), U.S. health spending performance certainly appears rather robust when compared with that of other major industrialized countries.
With regard to the other two measures, growth in nominal per capita health spending and real (medical price-adjusted) per capita spending, the United States ranked second and third, respectively. Concerning growth in nominal per capita health spending, the United States's 9.0 percent compound annual growth rate was only slightly below the 9.9 percent figure for the United Kingdom and well above the 7.5 percent for third-ranked Canada. Moreover, 1985 base-year spending in the United States (Exhibit 2) was 2.5 times the 1985 British level and over 35 percent higher than spending in any of these other countries. In addition, comparing growth in nominal per capita spending may not be a meaningful measure of relative health spending performance, given the sizable differences in the rates of inflation across countries.
Concerning the growth in real (medical price-adjusted) per capita spending, a proxy for growth in the volume and intensity of services, the United States ranked third, after Japan and France. This type of comparison (as in the case of excess health care inflation) is heavily dependent on the reliability and comparability of the medical care price deflators. As we have discussed elsewhere, both methodological and comparability problems exist in this area. 4 Nevertheless, if one discounts France, where the deflators appear to be the least comparable, only Japan, with a 1985 per person spending level less than half that in the United States, had a higher rate of volume and intensity growth.
Exhibit 4 displays the trend line between nominal per capita GDP and nominal per capita health spending for the twenty-four OECD countries in 1991. Health spending in the United States continues to be well above the level that would be predicted on the basis of the average relationship found for all of the OECD countries. In 1991 U.S. expenditures of $2,868 were almost $1,000 above the amount that would be predicted based on the average relationship found for the twenty-four countries. U.S. per capita health spending continues its unabated ascent above the trend line. 5 Taken together, all of these measures provide a picture of spending performance in which U.S. spending is the highest in the world. By most measures, U.S. spending is increasing at much higher rates than is true in other countries. The United States is giving up larger amounts of nonhealth-sector consumption and investment opportunities compared with other countries. Excess health care inflation is a far more serious problem in the United States than in other countries. Perhaps most telling is that between 1985 and 1991 U.S. nominal per capita health spending each year increased 70 percent faster than nominal per capita GDP (Exhibit 3), compared with only 35 percent in Canada, 19 percent in France, 13 percent in the United Kingdom, and 10 percent in Japan. Nominal per capita health spending increased 12 percent less rapidly than nominal per capita GDP in Germany. Moreover, the United States is moving increasingly away from the average relationship between health spending and GDP found in other OECD countries.
Availability And Use Of Services
Exhibit 5 contains information for 1990 (or the latest available year) on inpatient medical care beds per thousand population, inpatient days per capita, admission rates, average lengths-of-stay, occupancy rates, number of employees per bed, number of physicians per thousand, and physician contacts per capita. 6 The number of inpatient medical care beds ranged from 2.1 beds per thousand in Turkey to 16.7 beds in Iceland, with an OECD average of 9.0 beds. The United States (4.7 beds per thousand) had the fourth-lowest bed-to-population ratio. Days per capita ranged from 0.4 days per person per year in Turkey to 5.1 days in Iceland, with an OECD average of 2.7 days. The U.S. rate of 1.2 days per person per year ranked fifth from the bottom. The percentage of population admitted to an inpatient medical care facility varied from 5.4 percent in Turkey to 27.5 percent in Iceland, with an OECD average of 16.6 percent. The United States ( 13.7 percent) was well below average. Average length-of-stay per admission varied from 6.9 days in Turkey to 50.5 days in Japan, with an OECD average of 15.7 (14.2 excluding Japan). The United States (9.1 days) tied with Norway at fourth lowest. Occupancy rates ranged from 56.9 percent in Turkey to 88.5 percent in the Netherlands, with an OECD average of 78.5 percent. The U.S. occupancy rate (69.5 percent) was sixth lowest. The number of employees per bed ranged from 0.8 employees in Austria and Japan to 3.9 employees in Australia, with an OECD average of 2.0. The United States ranked second with 3.4 employees per bed. Only Australia and the United States had more than three employees per bed.
Concerning the availability and use of physician services, the physicianto-population ratios of the OECD countries ranged from 0.9 physicians per thousand in Turkey to 3.8 physicians in Spain, with an OECD average of 2.4 physicians. The United States (2.3 physicians per thousand) was close to the OECD average, although the U.S. mix is oriented much more toward specialists than toward generalists. Physician contacts per person per year ranged from 2.0 contacts in Turkey to 12.9 contacts in Japan, with an OECD average of 6.2 contacts. The United States (5.5 contacts) was below the OECD average.
As would be expected, these newer data on availability and use of inpatient medical care and physician services paint the same picture as those presented in Health Affairs, Fall 1991. Compared with the other major industrialized countries, the United States has fewer inpatient medical care beds, fewer days of care per person, the shortest lengths-of-stay, the lowest admission rate except for Japan, and the lowest occupancy rate. The fact that the United States has twice as many employees per bed as the average for the other five major countries is consistent with the hypothesis that more intensive care is rendered during a shorter stay in U.S. medical care facilities. In terms of physician service availability and use, while the numeric comparisons indicate an average physician-to-population ratio and fewer contacts per capita, significant differences in specialty mixes across countries temper the utility of these comparisons.
Health Outcome Measures
Exhibit 6 contains information for 1990 (or the latest available year) on infant mortality, life expectancy at birth, and life expectancy at age eighty for the twenty-four OECD countries. The 1990 infant mortality rates ranged from 4.6 deaths per thousand live births in Japan to 59.3 deaths in Turkey, with an OECD average of 9.7 deaths (7.5 excluding Turkey). The United States (9.1 deaths) had the fourth-highest infant mortality rate of the twenty-four countries 7 Male life expectancy at birth ranged from 75.9 years in Japan to 64.1 years in Turkey, with an OECD average of 72.6 years. The United States (72.0 years) ranked eighteenth along with Denmark. For females, life expectancy at birth ranged from 81.9 years in Japan to 68.4 years in Turkey, with an OECD average of 78.8 years. The United States (78.8 years) ranked fifteenth. A different picture emerges for life expectancy at age eighty. Male life expectancy at age eighty ranged from 7.4 years in Iceland to 5.2 years in Turkey, with an OECD average of 6.4 years. The United States (7.1 years) ranked second along with Canada. A similar picture emerges for females. Female life expectancy at age eighty ranged from 9.3 years in Canada to 5.9 years in Turkey, with an OECD average of 8.0 years. The United States (9.0 years) ranked second along with Iceland.
Implications Of The Data
One can hypothesize that the far more favorable ranking for the United readily answer these questions. These more recent data continue to reinforce the notion that by international standards the U.S. health care system is out of control. The United States generally has fewer beds, an average number of physicians, and lower service volumes, although the intensity of services appears to be higher. In the absence of more refined measures of outcomes, queuing costs, and consumer attitudes, it is difficult to assess what, if any, additional benefits accrue to Americans as a result of their far higher spending levels and rates of increase. Surveys of consumer and provider satisfaction give the American system low marks. 8 Health care reformers in the United States face an enormous task in reforming the country's health system. But as these data show, the United States has a much larger pool of money than any other country with which to transform its current system into one that meets other nations' standards of universal coverage and containment of costs.
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